Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Open-label, Two-arm, Parallel-group Randomized Trial Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

NCT06492720 is registered in ClinicalTrials.gov with NaviFUS Corporation as lead sponsor.

NCT NCT06492720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06492720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Open-label, Two-arm, Parallel-group Randomized Trial Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
Lead sponsor
NaviFUS Corporation
Phase
Not applicable
Overall status
Recruiting
Start date
September 1, 2024
Completion date
March 31, 2027
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistant epilepsy, epilepsy, epilepsy, temporal lobe, seizures, focal